Biomarker Research (Oct 2021)

Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients

  • Takahiro Einama,
  • Yoji Yamagishi,
  • Yasuhiro Takihata,
  • Takafumi Suzuki,
  • Tamio Yamasaki,
  • Yuichi Hirose,
  • Kazuki Kobayashi,
  • Naoto Yonamine,
  • Ibuki Fujinuma,
  • Takazumi Tsunenari,
  • Makiko Koga,
  • Yusuke Ishibashi,
  • Ken Nagata,
  • Takehiro Shiraishi,
  • Akiko Nakazawa,
  • Toshimitsu Iwasaki,
  • Eiji Shinto,
  • Kimi Kato,
  • Kimiya Sato,
  • Hideki Ueno,
  • Yoji Kishi,
  • Hitoshi Tsuda

DOI
https://doi.org/10.1186/s40364-021-00335-3
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 4

Abstract

Read online

Abstract The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %). A high correlation was observed between the expression of mesothelin and CA125 (P =0.0004). The co-expression of mesothelin and CA125 correlated with poor patient relapse-free survival (RFS) (P = 0.0001) and was identified as an independent predictor of RFS by Cox’s multivariate analysis. In conclusion, this is the first to report the prognostic significance of the co-expression of mesothelin and CA125 in breast cancer. The co-expression of mesothelin and CA125 may be clinically useful for prognostication after surgical therapy in patients with breast cancer.

Keywords